| ObjectiveTo observe the effect of Biejiaruangan capsule on clinical intervention and serum hepatic fibrosis markers in patients with hepatitis B virus infection-related cirrhosis.Methods60 patients with Child-Pugh A level liver cirrhosis characteristic of anti-virus indication and damp-heat from Chinese medicine symptom were recruited. The 60 patients were randomly divided equally into two groups, the treatment and control group. The treatment group was prescribed with Entecavir dispersible tablets combined with Biejiaruangan capsule, while the control group was prescribed with just Entecavir dispersible tablets. The overall treatment course was defined as 24 weeks. We will evaluated the 0-week, 12-week and 24-week indices of the two groups in terms of symptom integral, liver function indications, liver fibrosis indications,HBV quantity, vein diameter and spleen thickness. T-test was employed to evaluate the quantitative data and Ridt test for count data. For rank data χ2-test was used and Anova for multiple group analysis. The significant level was defined as P<0.05.Results1. From clinical symptom effect: the rate of overall effectiveness is 86.7% with 6patients cured, 12 patients marked improved and 8 patients improved in the treatment group, while the rate of overall effectiveness is 43.33% with 3 patients cured, 5patients marked improved and 5 patients improved in the control group. The clinical symptom effect of the treatment group in highly better than the control group(p<0.05).2. From liver function indices: after 12-week and 24-week treatment, the liver function indices including AST, ALT and TBil were improved for both treatment group and control group(P<0.05). The effect of treatment group was better than control group in the reducing ALT and increasing A and A/G(P<0.05).3. From serum markers: The increased serum HA, PC-III, LN, CV-IV type collagen was decreased in certain degree and demonstrated to be improved significantly(p<0.05). Compared with control group, Biejiaruangan capsule can reduce liver fibrosis indices apparently(p<0.05).4. From vein diameter and spleen thickness: The vein diameter and spleen thickness was reduced significantly after treatment(p<0.05) for treatment group, but not significant for control group. The level of reducing thickness was significant between the treatment group and control group(p<0.05).ConclusionsBiejiaruangan capsule combined with Entecavir dispersible tablets can improve bitter taste, anorexia and weak symptoms significantly and thus improve clinical symptoms effect in patients with hepatitis B virus infection-related cirrhosis. Meanwhile, it has great effect in hepatoprotection, reducing anti-fibrosis, and thus can postpone the liver cirrhosis progress. |
PDF Full Text Request